Latest Healthcare News

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Monash IVF Group reported a 5.6% rise in underlying EBITDA for FY25, navigating a declining Australian IVF market and operational challenges. The company sets a cautious FY26 NPAT guidance of $20-23 million while focusing on regaining market leadership and implementing safety reforms.

Monash IVF Group reported steady FY25 financial results with revenue and EBITDA growth, while managing clinical incidents and a CEO transition. The company outlines cautious FY26 guidance amid industry headwinds.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million in FY25 but saw an 8.1% decline in underlying net profit after tax to $27.4 million, impacted by market softness and operational incidents. The company outlines cautious FY26 guidance amid ongoing sector headwinds.

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

Cogstate Ltd has reported a strong FY25 with 22% revenue growth and a near doubling of profit before tax, declaring its first fully franked dividend and preparing to launch its inaugural AI-powered product in FY26.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

Cogstate Limited reported a 22.3% rise in total revenue to US$53.1 million for FY25, driven by strong Clinical Trials growth, while profit before tax nearly doubled to US$13.9 million. The company also declared its inaugural fully franked dividend.

Cryosite Limited reported a 12% increase in revenue for FY25, driven by a 58% surge in its ultra-frozen and cryogenic segment, while deferring dividends to fund expansion plans.

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.